| scholarly article | Q13442814 |
| P50 | author | Malcolm Brenner | Q6742199 |
| Helen Heslop | Q17386041 | ||
| Carlos A Ramos | Q38329408 | ||
| Barbara Pro | Q41599457 | ||
| Elizabeth J Shpall | Q87373605 | ||
| Stephen Gottschalk | Q89108137 | ||
| Catherine M Bollard | Q91774704 | ||
| Jack Meng-Fen Su | Q91889094 | ||
| Cliona M Rooney | Q96221187 | ||
| Adrian P Gee | Q98164172 | ||
| Luis E. Fayad | Q106561774 | ||
| Oumar Diouf | Q114435131 | ||
| George Carrum | Q114435134 | ||
| Yasmin Hazrat | Q114435138 | ||
| Vicky Torrano | Q114435144 | ||
| Andrea M Sheehan | Q114435162 | ||
| P2093 | author name string | Hao Liu | |
| Youli Zu | |||
| Daniel Lee | |||
| Stephanie Ku | |||
| P2860 | cites work | Adoptive immunotherapy for cancer: building on success | Q24546258 |
| T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia | Q24632975 | ||
| Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 | Q24633445 | ||
| Central memory and effector memory T cell subsets: function, generation, and maintenance | Q29615097 | ||
| Epstein-Barr virus: 40 years on | Q29617969 | ||
| Chimeric antigen receptor-modified T cells for acute lymphoid leukemia | Q29620130 | ||
| CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia | Q29620607 | ||
| Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 | Q29620608 | ||
| B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells | Q29620717 | ||
| The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease | Q31088065 | ||
| Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma | Q33222948 | ||
| Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients | Q33634455 | ||
| Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas | Q34147803 | ||
| A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy | Q34310840 | ||
| Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation | Q34312922 | ||
| HIV infection and lymphoma | Q34585452 | ||
| Hodgkin lymphoma | Q34643277 | ||
| CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients | Q34876434 | ||
| Progressive differentiation and selection of the fittest in the immune response | Q35014086 | ||
| Release of infectious Epstein-Barr virus by transformed marmoset leukocytes | Q35093948 | ||
| Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma | Q35264185 | ||
| Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4 | Q35556061 | ||
| Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? | Q35594089 | ||
| Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation | Q35849338 | ||
| A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma | Q35857642 | ||
| Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer | Q36059593 | ||
| Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates | Q36183567 | ||
| Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease | Q36399791 | ||
| Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. | Q36637195 | ||
| New response criteria for lymphomas in clinical trials | Q37179867 | ||
| Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies | Q40623874 | ||
| Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells | Q40826462 | ||
| An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs | Q40830952 | ||
| Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. | Q41034862 | ||
| Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides | Q43869097 | ||
| Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes | Q45551744 | ||
| Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. | Q45732919 | ||
| Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals | Q45862722 | ||
| Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. | Q46128909 | ||
| Revised response criteria for malignant lymphoma | Q47582438 | ||
| Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients | Q48030305 | ||
| Peptide length-based prediction of peptide-MHC class II binding | Q48430251 | ||
| Monoclonal antibody successes in the clinic | Q61163248 | ||
| Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones | Q67518698 | ||
| Donor T cells to treat EBV-associated lymphoma | Q72110900 | ||
| Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines | Q74211468 | ||
| Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies | Q83532433 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Epstein–Barr virus | Q6900 |
| cytotoxicity | Q246181 | ||
| membrane protein | Q423042 | ||
| P304 | page(s) | 798-808 | |
| P577 | publication date | 2013-12-16 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins | |
| P478 | volume | 32 |
| Q36003208 | A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine |
| Q57072187 | A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection |
| Q47549907 | A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy |
| Q36248964 | A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma |
| Q35121627 | A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer |
| Q42688168 | A roadmap for discovery and translation in lymphoma. |
| Q92151824 | A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells |
| Q40080577 | Achievement of disease control with donor-derived EB virus-specific cytotoxic T cells after allogeneic peripheral blood stem cell transplantation for aggressive NK-cell leukemia |
| Q38848219 | Adoptive Cellular Therapy (ACT) for Cancer Treatment |
| Q92764877 | Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR |
| Q52721827 | Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders. |
| Q26782845 | Adoptive T-Cell Immunotherapy |
| Q26775720 | Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances |
| Q39044990 | Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine. |
| Q38525041 | Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors |
| Q37684247 | An AIDS-defining neoplasm in a 30-year-old man on highly active antiretroviral therapy: a forgotten diagnosis? |
| Q28551080 | An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers |
| Q38544740 | Antigen-specific T cell therapies for cancer |
| Q64374731 | Are we there yet? The never-ending quest for an Epstein-Barr virus vaccine |
| Q35591760 | Blood and marrow transplant clinical trials network state of the Science Symposium 2014 |
| Q33724290 | Boolean immunotherapy: reversal of fortune |
| Q35653249 | Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy |
| Q52658445 | CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing? |
| Q36519358 | CAR-T Cell Therapy for Lymphoma. |
| Q47289766 | Cell therapies for hematological malignancies: don't forget non-gene-modified t cells! |
| Q89669654 | Cellular Immunotherapy in Lymphoma: Beyond CART Cells |
| Q38787776 | Checkpoint inhibition and cellular immunotherapy in lymphoma |
| Q38822525 | Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science |
| Q38913549 | Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. |
| Q88573551 | Chimeric antigen receptor-modified T cells: CD19 and the road beyond |
| Q40084076 | Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes |
| Q35563824 | Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. |
| Q45870279 | Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy |
| Q39016336 | Current Trends and Alternative Scenarios in EBV Research |
| Q64074548 | Current advances in Hodgkin’s lymphoma |
| Q38848990 | Current and future immunotherapeutic approaches in Hodgkin lymphoma |
| Q38662372 | Current treatment approaches for NK/T-cell lymphoma. |
| Q85774777 | Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment |
| Q39170011 | Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities |
| Q89777680 | Developing T-cell therapies for lymphoma without receptor engineering |
| Q47267330 | Developing T-cell therapies for lymphoma without receptor engineering. |
| Q40411216 | Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. |
| Q40441016 | EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas |
| Q38812004 | EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management |
| Q59351745 | EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation |
| Q39284101 | Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL). |
| Q90208950 | Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to viral directed immunotherapy |
| Q64120868 | Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders |
| Q26822550 | Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target |
| Q58616015 | Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy |
| Q90406888 | Epstein-Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Selection of Diverse T Cell Receptor α and β Repertoires |
| Q40073030 | Epstein-Barr Virus LMP1 Mediated Oncogenicity. |
| Q64269086 | Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma |
| Q38720593 | Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options |
| Q38968588 | Epstein-Barr virus: more than 50 years old and still providing surprises. |
| Q35053650 | Epstein-barr virus vaccines |
| Q92337122 | Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors |
| Q33456742 | Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease |
| Q54962558 | Evaluation of latent membrane protein 1 and microRNA-155 for the prognostic prediction of diffuse large B cell lymphoma. |
| Q41490849 | Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement |
| Q35812943 | Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir |
| Q38693404 | Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy |
| Q30244110 | Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases |
| Q45862561 | Finding suitable targets is the major obstacle to cancer gene therapy. |
| Q30275251 | Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas |
| Q38230157 | Gene-modified cells for stem cell transplantation and cancer therapy |
| Q92801388 | Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type |
| Q57039737 | HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals |
| Q35880618 | Haematological malignancies: at the forefront of immunotherapeutic innovation |
| Q64100454 | Harnessing CD8 T Cells Under HIV Antiretroviral Therapy |
| Q59128393 | Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders |
| Q40590036 | Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes. |
| Q59349091 | How I treat T-cell chronic active Epstein-Barr virus disease |
| Q35684896 | Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma. |
| Q39097082 | Human immunity against EBV-lessons from the clinic. |
| Q36447548 | IL-12-Dependent Cytomegalovirus-Specific CD4+ T Cell Proliferation, T-bet Induction, and Effector Multifunction during Primary Infection Are Key Determinants for Early Immune Control |
| Q35915780 | Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis Pathogenesis. |
| Q62050532 | Identifying neoantigens for use in immunotherapy |
| Q92151588 | Immune Control and Vaccination against the Epstein-Barr Virus in Humanized Mice |
| Q38263108 | Immune-based therapies for childhood cancer. |
| Q38840989 | Immunoselection techniques in hematopoietic stem cell transplantation |
| Q38803361 | Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma |
| Q38778924 | Immunotherapy against cancer-related viruses |
| Q92290251 | Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies |
| Q89626900 | Immunotherapy of lymphomas |
| Q33941012 | Immunotherapy: opportunities, risks and future perspectives |
| Q41879726 | Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice |
| Q38912826 | Improving the safety of T-Cell therapies using an inducible caspase-9 gene |
| Q57493527 | In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas |
| Q89453206 | Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes |
| Q48669191 | International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). |
| Q36757012 | Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs |
| Q91807425 | Long-term eradication of extranodal natural killer/T-cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells in vivo |
| Q36035448 | Malignancies in systemic lupus erythematosus: a 2015 update |
| Q90630495 | Management of NK/T-Cell Lymphoma, Nasal Type |
| Q38912282 | Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy |
| Q52676514 | Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. |
| Q35589035 | Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency. |
| Q36928580 | Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy |
| Q64085662 | Molecular pathogenic pathways in extranodal NK/T cell lymphoma |
| Q59340620 | Moving things forward in Hodgkin lymphoma |
| Q39098289 | Non-anaplastic peripheral T-cell lymphoma in children and adolescents--a retrospective analysis of the NHL-BFM study group |
| Q57468335 | Novel Immunotherapies for T Cell Lymphoma and Leukemia |
| Q55094448 | Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma. |
| Q92349386 | Novel Synthetic DNA Immunogens Targeting Latent Expressed Antigens of Epstein-Barr Virus Elicit Potent Cellular Responses and Inhibit Tumor Growth |
| Q39187452 | Novel agents in classical Hodgkin lymphoma |
| Q26777394 | Novel immunotherapies in lymphoid malignancies |
| Q38568602 | Novel roles and therapeutic targets of Epstein-Barr virus-encoded latent membrane protein 1-induced oncogenesis in nasopharyngeal carcinoma |
| Q38661106 | Novel targets for natural killer/T-cell lymphoma immunotherapy |
| Q39043082 | Novel treatment concepts in Hodgkin lymphoma. |
| Q38604100 | Opportunities and challenges for the cellular immunotherapy sector: a global landscape of clinical trials. |
| Q64086953 | Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders |
| Q89940657 | Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies |
| Q50581082 | Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. |
| Q89927507 | Pathobiology and Treatment of Lymphomatoid Granulomatosis; A Rare EBV-Driven Disorder |
| Q34605894 | Pediatric lymphomas and histiocytic disorders of childhood |
| Q38335303 | Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions |
| Q48321203 | Pharmacotherapeutic Management of Pediatric Lymphoma. |
| Q38823260 | Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies |
| Q26798038 | Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment |
| Q40253951 | Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy |
| Q64104879 | Progress in EBV Vaccines |
| Q37203522 | Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients. |
| Q34507561 | Prospects for gene-engineered T cell immunotherapy for solid cancers. |
| Q38789518 | Recent advances in T-cell immunotherapy for haematological malignancies |
| Q42842493 | Reply to S. Yuan et al. |
| Q30580134 | Reversal of tumor immune inhibition using a chimeric cytokine receptor |
| Q64879912 | Revolutionary changes in salvage treatment for Hodgkin lymphoma: toward a chemotherapy-free future. |
| Q57176933 | Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target |
| Q52597541 | Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. |
| Q58721423 | Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma |
| Q37706835 | Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens |
| Q63101722 | Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination |
| Q64376731 | T Cell Tumor Immunotherapy: Oncolysis Beats Lymphodepletion |
| Q92245345 | T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance |
| Q26853345 | T lymphocytes targeting native receptors |
| Q90176790 | T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies |
| Q38597252 | T-Cell Responses to EBV. |
| Q34550760 | T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control |
| Q40837271 | Targeting CD19: the good, the bad, and CD81. |
| Q53123844 | Targeting Immune System Alterations in Hodgkin Lymphoma. |
| Q35236817 | The B subunit of Escherichia coli enterotoxin helps control the in vivo growth of solid tumors expressing the Epstein-Barr virus latent membrane protein 2A. |
| Q30278553 | The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment |
| Q60019698 | The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation |
| Q92860015 | The Global Landscape of EBV-Associated Tumors |
| Q41219311 | The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder |
| Q91812783 | The Role of Dendritic Cells in Immune Control and Vaccination against -Herpesviruses |
| Q37517482 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia |
| Q45346558 | The cancer-virus cures |
| Q89828865 | The efficacy and safety of Epstein-Barr virus-specific antigen peptide-activated cytotoxic T-cells treatment for refractory or recurrent angioimmunoblastic T-cell lymphoma: A prospective clinical observational study |
| Q36457849 | The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma |
| Q35945221 | The role of the tumor microenvironment in HIV-associated lymphomas |
| Q59360113 | The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma |
| Q42702234 | Trial Watch: Adoptive cell transfer for anticancer immunotherapy |
| Q47218634 | Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma |
| Q38410415 | Uncommon non-Hodgkin lymphomas of childhood: pathological diagnosis, clinical features and treatment approaches |
| Q37058110 | Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies |
| Q39043404 | Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update |
| Q42654381 | Virus-Specific T Cells for the Immunocompromised Patient |
| Q36286889 | Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway |
Search more.